Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Masupirdine - Suven Life Sciences

Drug Profile

Masupirdine - Suven Life Sciences

Alternative Names: M1; M1 of SUVN-502; SUVN502; SVN-502

Latest Information Update: 27 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suven Life Sciences
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Indoles; Piperazines; Small molecules
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease; Schizophrenia

Highest Development Phases

  • Phase II Alzheimer's disease; Schizophrenia
  • Preclinical Dementia
  • No development reported Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease

Most Recent Events

  • 05 Nov 2019 Suven Life Sciences completes a phase II trial in Alzheimer's disease (Adjunctive treatment) in USA (PO) (NCT02580305)
  • 14 Jul 2019 Pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2019 (AAIC-2019)
  • 14 Jul 2019 Pharmacokinetics and adverse events data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2019 (AAIC-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top